Arena Pharmaceuticals Presented Preclinical Data for APD418 in Development for Treatment of Decompensated Heart Failure at American Heart Association Scientific Sessions
Retrieved on:
Tuesday, November 13, 2018
SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA)presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), 3 adrenergic receptor (AdrR) selective antagonist,at the American Heart Association Scientific Sessions 2018 .
Key Points:
- SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA)presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), 3 adrenergic receptor (AdrR) selective antagonist,at the American Heart Association Scientific Sessions 2018 .
- APD418 is being developed to improve cardiac contractility with minimal effect on heart rate and blood pressure for decompensated heart failure (DHF).
- APD418 is a 3 adrenergic receptor (AdrR) selective antagonist designed to improve cardiac contractility with minimal effect on heart rate and blood pressure.
- Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.